Source study found

Story checked

Michigan Medicine study reveals how diabetes drug reduces stroke risk (opens in a new tab)

news-medical.net · 2026-10-28

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

4 supported
2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Michigan Medicine study reveals how diabetes drug reduces stroke risk

news-medical.net · 2026-10-28

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Every claim we could check holds up. Four of six claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

4 supported
2 not covered

Open claim evidence

The source study

SGLT1/2 inhibitor sotagliflozin, but not SGLT2-selective inhibitor empagliflozin, attenuates platelet activation and thrombosis

The Journal of Clinical Investigation · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredIn mice with injured blood vessels, sotagliflozin reduced clot formation by approximately 60%, compared with just 5-10% in animals treated with empagliflozin.View evidenceHide evidence

As statedapproximately 60% vs 5-10%

Why this verdict

The abstract-level profile supports the qualitative direction: sotagliflozin reduced thrombus formation in mouse models and empagliflozin had minor to no effects. However, the abstract profile provides no numeric effect sizes, no 60% versus 5–10% comparison, and no detailed confirmation of the specific injured-vessel model. Those quantitative details are therefore not verifiable at abstract depth.

Study evidence

Sotagliflozin inhibited platelet activity and reduced thrombus formation in in vivo mouse models.

“Employing ex vivo models using blood from healthy donors or T2DM patients, and in vivo mouse models, we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”

Claim 2 of 6Not coveredThe article says removing SGLT1 from platelets in mice reduced blood clot formation by about 40%, but genetic removal or blocking with the SGLT1-selective inhibitor mizagliflozin did not fully reproduce sotagliflozin's effects.View evidenceHide evidence

As statedabout 40%

Why this verdict

The abstract supports that platelet-specific SGLT1 deletion in mice reduced platelet integrin activation and thrombus formation. But it does not provide the stated ~40% magnitude, does not mention mizagliflozin, and does not state that genetic removal or SGLT1-selective blocking failed to fully reproduce sotagliflozin’s effects. Those parts require full-text evidence and are not verifiable from the abstract profile.

Study evidence

Platelet-specific deletion of SGLT1 (Slc5a1fl/fl; Gp1ba-Cre+) reduced platelet integrin activation in mice.

“Finally, a platelet-specific deletion of SGLT1 via Slc5a1fl/fl Gp1ba-Cre+ mice resulted in reduced platelet integrin activation and thrombus formation.”

Claim 3 of 6SupportedResearchers at Michigan Medicine have uncovered a mechanism that may explain why sotagliflozin, an FDA-approved diabetes medication marketed as Inpefa, reduces the risk of heart attack and stroke.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the central framed claim: sotagliflozin was associated in clinical trials with reduced myocardial infarction and stroke, and this paper presents platelet/thrombosis findings as a potential mechanistic explanation. The story uses hedging (“may explain”), which matches the abstract’s mechanistic framing. The supplied paper profile does not independently verify the regulatory/brand detail (“FDA-approved,” “Inpefa”), but that is ancillary to the scientific claim.

Study evidence

Sotagliflozin produced an inhibitory effect on platelet activity and thrombus formation in ex vivo assays using human blood from healthy donors and T2DM patients.

“Employing ex vivo models using blood from healthy donors or T2DM patients... we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”

Study evidence

Sotagliflozin inhibited platelet activity and reduced thrombus formation in in vivo mouse models.

“Employing ex vivo models using blood from healthy donors or T2DM patients, and in vivo mouse models, we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”

Claim 4 of 6SupportedIn a series of laboratory experiments, the research team found that the drug helps prevent excessive platelet activation, a process that can lead to dangerous blood clots that block flow to the heart and brain.View evidenceHide evidence

Why this verdict

The profile reports ex vivo human blood/platelet assays and in vivo mouse models showing sotagliflozin inhibited platelet activity and thrombus formation. Because these are laboratory experimental settings, the story’s causal wording about helping prevent platelet activation/clot formation is supported insofar as it is confined to the lab and animal evidence described.

Study evidence

Sotagliflozin produced an inhibitory effect on platelet activity and thrombus formation in ex vivo assays using human blood from healthy donors and T2DM patients.

“Employing ex vivo models using blood from healthy donors or T2DM patients... we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”

Study evidence

Sotagliflozin inhibited platelet activity and reduced thrombus formation in in vivo mouse models.

“Employing ex vivo models using blood from healthy donors or T2DM patients, and in vivo mouse models, we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”

Claim 5 of 6SupportedThe findings, published in the Journal of Clinical Investigation, provide new insight into cardiovascular benefits of the drug that extend beyond blood sugar control.View evidenceHide evidence

Why this verdict

The abstract frames the findings as a potential explanation for sotagliflozin’s cardiovascular protection and as a platelet/thrombus-related mechanism distinct from glucose lowering. The supplied profile does not itself verify the Journal of Clinical Investigation publication detail, but the substantive claim about mechanistic insight beyond blood sugar control is supported.

Study evidence

Sotagliflozin produced an inhibitory effect on platelet activity and thrombus formation in ex vivo assays using human blood from healthy donors and T2DM patients.

“Employing ex vivo models using blood from healthy donors or T2DM patients... we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”

Study evidence

Sotagliflozin inhibited platelet activity and reduced thrombus formation in in vivo mouse models.

“Employing ex vivo models using blood from healthy donors or T2DM patients, and in vivo mouse models, we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”

Claim 6 of 6SupportedResearchers conducted a head-to-head comparison between sotagliflozin and empagliflozin, and sotagliflozin limited platelet activation in blood samples from both healthy volunteers and people with type 2 diabetes while empagliflozin had little to no effect.View evidenceHide evidence

Why this verdict

The abstract explicitly states that ex vivo models using blood from healthy donors or T2DM patients showed inhibitory effects of sotagliflozin on platelet activity and thrombus formation, while empagliflozin had minor to no effects. This directly supports the head-to-head comparison as framed for blood samples.

Study evidence

Sotagliflozin produced an inhibitory effect on platelet activity and thrombus formation in ex vivo assays using human blood from healthy donors and T2DM patients.

“Employing ex vivo models using blood from healthy donors or T2DM patients... we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Safety/hemostasis element: the abstract reports no observed impact of sotagliflozin on hemostasis in mouse assessments.
The supplied story claims and caveats do not mention the paper’s hemostasis/bleeding assessment. This is a material paper element because it affects interpretation of antithrombotic effects as potentially not impairing normal hemostasis, at least in mice.
From in_vivo_mouse_hemostasis_assays
Limitation: the abstract profile lacks quantitative effect sizes, sample sizes, statistical measures, dosing/exposure details, and detailed assay parameters for the ex vivo and in vivo comparisons.
The story presents specific numerical reductions for mouse and SGLT1-deletion findings, but the abstract-level profile does not provide those numbers or supporting statistical/methodological detail. The story caveats do not acknowledge this abstract-level evidentiary limitation.
From ex_vivo_human_platelet_assays; in vivo mouse thrombosis experiments (drug comparison); platelet-specific Slc5a1 knockout

5 things the story did carry across

Primary ex vivo human blood finding: sotagliflozin inhibited platelet activation and thrombus/thrombus-like formation in blood from healthy donors and people with T2DM, while empagliflozin had minor to no effects.
Primary in vivo animal finding: sotagliflozin reduced platelet activity/thrombus formation in mouse models, whereas empagliflozin had minor to no effects.
Mechanistic genetic element: platelet-specific SGLT1 deletion in mice reduced platelet integrin activation and thrombus formation, supporting platelet SGLT1 as a contributor to thrombosis.
Clinical-context element: prior clinical trials showed reduced myocardial infarction and stroke with sotagliflozin, motivating a mechanistic study rather than constituting a new clinical outcomes trial.
Translational limitation: mouse thrombosis and mouse hemostasis findings do not by themselves establish human clinical effects or human bleeding risk.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

ex vivo human

1Lead resultex vivo humanSotagliflozin (dual SGLT1/2 inhibitor) directly attenuates platelet activation and thrombus formation more than the SGLT2-selective inhibitor empagliflozin, based on ex vivo assays using human blood.ex vivo human platelet assaysExpand

In plain English

In ex vivo assays using human whole blood or platelets from healthy donors and patients with T2DM, sotagliflozin (dual SGLT1/2 inhibitor) produced an inhibitory effect on platelet activity and thrombus formation, whereas the SGLT2-selective inhibitor empagliflozin showed minor to no effects; the abstract additionally reports no observed impact of sotagliflozin on hemostasis.

Key findings

Sotagliflozin produced an inhibitory effect on platelet activity and thrombus formation in ex vivo assays using human blood from healthy donors and T2DM patients.
Empagliflozin showed minor to no effects on platelet activity and thrombus formation in the same ex vivo human assays.

“Employing ex vivo models using blood from healthy donors or T2DM patients... we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”

What this piece can’t prove

3 further details could not be confirmed from the summary.

2in vivo animalSotagliflozin reduces thrombosis in vivo without impairing hemostasis, based on mouse models.in vivo mouse thrombosis experiments (drug comparison)Expand

In plain English

In in vivo mouse models, sotagliflozin inhibited platelet activity and reduced thrombus formation without affecting hemostasis, whereas the SGLT2-selective inhibitor empagliflozin showed minor to no effect on these endpoints.

Key findings

Sotagliflozin inhibited platelet activity and reduced thrombus formation in in vivo mouse models.
Empagliflozin showed minor to no effect on platelet activity and thrombus formation in the same in vivo mouse models.

“Employing ex vivo models using blood from healthy donors or T2DM patients, and in vivo mouse models, we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”

What this piece can’t prove

This summary is based only on the abstract; the abstract does not report experimental details (mouse model type, thrombosis induction method, dosing, timing, sample sizes, or statistics).

2 further details could not be confirmed from the summary.

3in vivo animalSotagliflozin reduces thrombosis in vivo without impairing hemostasis, based on mouse models.in vivo mouse hemostasis assaysExpand

In plain English

Abstract reports that sotagliflozin inhibited platelet activity and thrombus formation in ex vivo and in vivo models and that, in mouse hemostasis assessments, sotagliflozin had no impact on hemostasis.

Key findings

No impact on hemostasis was observed with sotagliflozin in mouse hemostasis/bleeding assessments.
Sotagliflozin inhibited platelet activation and thrombus formation in ex vivo human blood and in vivo mouse models; empagliflozin showed minor to no effects.

“Further, no impact on hemostasis was observed with sotagliflozin.”

What this piece can’t prove

Summary is based solely on the abstract; full methods, numeric results, sample sizes, and statistical analyses are not available here.
Abstract does not specify the specific mouse hemostasis assays, dosing regimen, timing, mouse strain, or comparator details for the hemostasis assessments.
No quantitative bleeding metrics or thresholds reported; cannot assess magnitude or precision of 'no impact' conclusion.

2 further details could not be confirmed from the summary.

4in vivo animalPlatelet SGLT1 is a mechanistic driver of platelet activation/thrombosis: platelet-specific SGLT1 deletion reduces integrin activation and thrombus formation.platelet-specific Slc5a1 knockout (Slc5a1fl/fl; Gp1ba-Cre+)Expand

In plain English

The paper reports that platelet-specific genetic deletion of SGLT1 (Slc5a1fl/fl; Gp1ba-Cre+) in mice resulted in reduced platelet integrin activation and reduced thrombus formation, indicating platelet SGLT1 contributes to platelet activation and thrombosis. The abstract does not provide quantitative effect sizes, sample sizes, genotyping/controls, or statistical details.

Key findings

Platelet-specific deletion of SGLT1 (Slc5a1fl/fl; Gp1ba-Cre+) reduced platelet integrin activation in mice.
Platelet-specific deletion of SGLT1 (Slc5a1fl/fl; Gp1ba-Cre+) reduced thrombus formation in vivo.

“Finally, a platelet-specific deletion of SGLT1 via Slc5a1fl/fl Gp1ba-Cre+ mice resulted in reduced platelet integrin activation and thrombus formation.”

What this piece can’t prove

Abstract does not provide genotyping, recombination efficiency, controls, sample sizes, or replication details for the platelet-specific knockout experiments.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer